AMAlun Meggy

Alun Meggy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alun Meggy has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Sexual dysfunction outcomes and reporting disparities after multimodal treatment for rectal cancer: A systematic review and narrative synthesis

    by Vignesh Lakshmanan, Jennifer Waterman, Alun Meggy, Jared Torkington, Julie A. Cornish

    Background: Sexual dysfunction is a recognised adverse outcome after rectal cancer treatments, yet reporting is predominantly male‐focused, with female sexual dysfunction less consistently assessed or reported. This systematic review aimed to assess sexual health domains studied, examine sex‐based reporting disparities, and identify limitations in the current evidence. Methods: A systematic review and narrative synthesis were conducted in accordance with PRISMA and registered with PROSPERO (CRD420251178502). PubMed/MEDLINE, EMBASE, Scopus, CINAHL Plus, PsycINFO, and Cochrane Library were searched from March 1995 to March 2025, with an updated search to March 2026. Eligible studies included adults treated for rectal cancer in whom sexual function outcomes were assessed using International Index of Erectile Function (IIEF) and/or Female Sexual Function Index (FSFI), with additional related patient‐reported outcome measures (PROMs) accepted where relevant. Risk of bias was assessed using RoB 2 and MINORS. Results: Twenty‐five studies involving 4,071 patients were included. Participants were predominantly male (65.8%), while women comprised 34.2%. PROM reporting was inconsistent; only eight studies reported both total and domain‐level results. Sexual outcomes were most consistently reported for men, particularly erectile and ejaculatory function, whereas female outcomes were often reduced to overall scores. Five studies restricted sexual outcome assessment and analysis to men. Only six reported response rates, and missing PROM data handling was not described. Key contextual variables, including sexual activity, sexual orientation, sexual practices, and menopausal status, were rarely captured. Conclusions: Sexual function outcomes after rectal cancer treatment are inconsistently reported, with low certainty. Female sexual dysfunction remains under‐represented. Standardised, inclusive sex‐specific reporting and development of a core outcome set are needed.

  • Open Access

    Phase One Development of a Patient-Reported Outcome Measure for Low Anterior Resection Syndrome

    by Alexandra Coxon-Meggy, Emily Farrow, Laura Knight, Ian Bissett, Liliana Bordeianou, Marylise Boutros, Jennifer Burch, Peter Christensen, Neil Corrigan, Julie Croft, et al.

    Background: The Low Anterior Resection Syndrome (LARS) score is an internationally validated instrument for identifying bowel dysfunction following anterior resection for rectal cancer. Although widely used, it has been shown to have limited sensitivity for capturing the impact of LARS on daily-life and response to treatment. We have therefore developed a novel patient-reported outcome measure (PROM): the LARS Impact and Consequences Assessment Tool (LARS-ICAT). Methods: Initial development of LARS-ICAT followed a five-stage process following established PROM development guidance. Stage one established the conceptual foundation through previously published Delphi consensus. Stage two involved item generation, followed by evaluation of content validity through patient focus groups (n=11) in stage three. Stage four comprised iterative expert review and refinement through clinical consensus with patient involvement. Stage five involved cognitive interviews with patients conducted across five rounds (n=23). Results: Several items identified through the Delphi consensus were reworded as they included multiple concepts. A one-month recall period was selected, with six and four response options for symptom and consequence items respectively. Additional consequence items, including impact on sleep and transport use, were incorporated. Focus groups and clinicians emphasised the importance of capturing individual symptom burden, leading to the addition of symptom bother scales. These iterative refinements culminated in LARS-ICAT v2.6. Conclusions: LARS-ICAT is a novel PROM designed to assess symptom burden and treatment response in LARS. Future studies will assess its psychometric properties. Once validated, LARS-ICAT will provide a comprehensive, patient-centred assessment of LARS, enhancing our ability to manage this challenging condition. Strengths and Limitations: The LARS-ICAT was specifically designed to measure change over time and responsiveness to treatment, addressing important limitations of existing instruments, such as the LARS score. Input from patients and experts across multiple countries improved the content validity and cross-cultural relevance of the PROM. This work also led to the establishment of the LARS Collaborative, an international research group dedicated to advancing education, engagement and understanding of LARS and its management. The study included only English-speaking participants, which may limit the generalisability of the instrument to non-English-speaking populations until formal translation, linguistic validation and cross-cultural validation has been undertaken.

  • Open Access

    Management of PErioperative Anemia in EmeRgency Laparotomy Patients (PEARL Study)

    by Vignesh Lakshmanan, Dhanya Lakxmi Nantha Kumar, Carven Chin, Alexander H. M. Lukaszewicz, Alun Meggy, Louise M. Silva, Jared Torkington, Julie A. Cornish

    Background/Aim: There has been a drive on improving outcomes after Emergency Laparotomy (EmLap) due to the National Emergency Laparotomy Audit (NELA). This has focused mainly on preoperative and intraoperative management with less emphasis on other perioperative aspects. We aimed to assess the prevalence of anemia in EmLap patients and its management in a perioperative period, exploring the gaps in anemia care. Methods: A retrospective cohort study of prospectively maintained database of 1055 EmLap patients (2016–2019) from a UK tertiary center was performed. Data were extracted from the NELA database, POLO study, electronic records (Welsh Clinical Portal). Statistics were performed in SPSS v27. Results: Among 740 patients, 77% underwent open surgery, with mean age of 61.9 years (range 18–98), median age of 65 years, and roughly equal sex distribution (female 54%). The median preoperative NELA risk was 3.6% (IQR 1.1–9.8). Over a quarter of patients (28.6%) were anemic on admission. Anemic patients had significantly longer hospital stays (median 12 days; >/ = 11 days, p = 0.008) and higher stoma formation rates (54.1% moderate anemia vs. 34.3% nonanemic; p = 0.002). Three‐quarters of patients (74.2%) were anemic at discharge (median Hb: 108 g/L, range: 74–129 g/L) but only 12% were treated with oral or IV iron or blood transfusion; only 10% had anemia reported in their discharge letters with appropriate follow‐up and management plan. Conclusions: Anemia in patients undergoing emergency laparotomy is significantly under‐recognized and inadequately managed at discharge, despite recognized increased morbidity. A structured pathway for continuing anemia treatment and discharge planning is urgently needed to improve outcomes.

  • Open Access

    The invite study: incisional hernia prevention: prophylactic mesh from the patient’s perspective

    by Laurie Smith, Laura Knight, Alun Meggy, Tessa Watts, Jared Torkington, Julie Cornish

    Purpose: Mesh-augmented abdominal wall closure (Mesh prophylaxis) reduces incisional hernia rates in high-risk patients. In spite of a large body of evidence supporting its efficacy and safety, use of mesh prophylaxis is low in the US and UK, possibly due to negative perceptions of surgical mesh (1-2) . This study aimed to assess the acceptability of mesh to patients and determine factors that influence acceptability. Methods: Following ethical approval, a convergent mixed-methods study was conducted whereby patients who had undergone elective or emergency surgery ( n=332) were approached to participate in a questionnaire assessing knowledge and opinions regarding mesh prophylaxis Semi-structured interviews were conducted in a subset of participants ( n =12) and thematic analysis performed. Results: 120 questionnaires were returned with a response rate of 36.1%. The majority (61.8%) of participants had heard of surgical mesh, with half (51.7%) having a negative association, driven by the media. Half (50%) of participants had pre-existing concerns about mesh, however the majority (91%) felt mesh prophylaxis to be acceptable, findings which were echoed in the qualitative component. Analysis of interview data identified three themes: "Knowledge of mesh" and "Acceptability of mesh", which triangulated with findings in the survey data and "Shared decision-making", which explored how participants wanted to receive information about mesh. Factors affecting acceptability of mesh included the nature of information given to patients, and the way in which it was delivered. Conclusions: Despite negative pre-conceptions, mesh prophylaxis is broadly acceptable to patients. The results of this work will be used to develop patient resources to support mesh prophylaxis. Future mixed-methods studies identifying the surgeons’ barriers to use of mesh are needed to allow targeted implementation of prophylactic mesh.


  • Open Access

    Psychosocial outcomes following emergency laparotomy (POLO) study: a study protocol for a multicentre mixed-methods prospective cohort study assessing the psycho-social outcomes following emergency laparotomy in adults

    by Louise Silva, Sarah Abbas Mohamed, Alun Meggy, Jene Hwei Ng, Jared Torkington, Susan Moug, Tessa Watts, Jonathan Bisson, Julie A Cornish

    Introduction Morbidity from an emergency laparotomy (EmLap) is difficult to define and poorly understood. Morbidity is a holistic concept, reliant upon an interplay of bio-psychosocial outcomes that evolve long after discharge. To date, no previous study has explored the psychosocial outcomes following EmLap as a collective, nor their change over time. This study aims to describe the holistic morbidity following EmLap within the first year following surgery. Methods and analysis This is a multicentre, mixed-methods prospective 12-month cohort study with two participant populations: patient participants and family caregivers (FCGs). A target of 160 adult patients who undergo EmLap and can give informed consent will be included in the patient participant group. Patient participants will be asked to complete three patient surveys, incorporating validated patient-reported outcome measures (PROMs) to assess bio-psychosocial outcomes (EuroQol five-dimension five-level (EQ5D-5L), Gastrointestinal Quality Life Index-36, Patient Health Questionnaire-9, Generalised Anxiety Disorder 7, International Trauma Questionnaire, Caregiver Interaction Scale and Fatigue Severity Scale) in the 12 months following surgery. A subgroup of 15 patient participants will be asked to take part in two semistructured interviews at 6 and 12 months. A target of 15 associated family caregivers will be included in the FCG group. FCGs will be asked to take part in a semi-structured interview at 6 months to assess the EmLap impact on the wider support network. The primary outcome will be a change in quality of life (EQ5D-5L) at 12 months. Secondary outcomes will be changes in bio-psychosocial status at 3 and 12 months. Qualitative analysis will allow contextualisation of PROMS and further explore themes of EmLap morbidity. It is anticipated that the results of this study will help inform and develop standards of aftercare for future EmLap patients. Ethics and dissemination This study has received ethical approval (Wales REC7;12/WA/0297) and will be undertaken in accordance with the principles of Good Clinical Practice. We intend to disseminate study results in peer-reviewed journals and medical conferences, as well as a lay report to study participants. Trial registration number Clinical Trials.gov NCT05281627.